PTCT vs. SMMT, ITCI, GMAB, MRNA, VTRS, RDY, ASND, SRPT, PCVX, and QGEN
Should you be buying PTC Therapeutics stock or one of its competitors? The main competitors of PTC Therapeutics include Summit Therapeutics (SMMT), Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Moderna (MRNA), Viatris (VTRS), Dr. Reddy's Laboratories (RDY), Ascendis Pharma A/S (ASND), Sarepta Therapeutics (SRPT), Vaxcyte (PCVX), and Qiagen (QGEN). These companies are all part of the "pharmaceutical products" industry.
PTC Therapeutics vs.
PTC Therapeutics (NASDAQ:PTCT) and Summit Therapeutics (NASDAQ:SMMT) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, dividends, community ranking, valuation, profitability, risk, earnings, institutional ownership and media sentiment.
PTC Therapeutics has a beta of 0.66, suggesting that its stock price is 34% less volatile than the S&P 500. Comparatively, Summit Therapeutics has a beta of -1.04, suggesting that its stock price is 204% less volatile than the S&P 500.
In the previous week, Summit Therapeutics had 1 more articles in the media than PTC Therapeutics. MarketBeat recorded 11 mentions for Summit Therapeutics and 10 mentions for PTC Therapeutics. PTC Therapeutics' average media sentiment score of 1.12 beat Summit Therapeutics' score of 0.68 indicating that PTC Therapeutics is being referred to more favorably in the media.
PTC Therapeutics presently has a consensus price target of $64.00, indicating a potential upside of 13.74%. Summit Therapeutics has a consensus price target of $34.11, indicating a potential upside of 68.53%. Given Summit Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Summit Therapeutics is more favorable than PTC Therapeutics.
PTC Therapeutics received 261 more outperform votes than Summit Therapeutics when rated by MarketBeat users. Likewise, 61.87% of users gave PTC Therapeutics an outperform vote while only 58.48% of users gave Summit Therapeutics an outperform vote.
Summit Therapeutics has a net margin of 0.00% compared to PTC Therapeutics' net margin of -50.32%. PTC Therapeutics' return on equity of 0.00% beat Summit Therapeutics' return on equity.
Summit Therapeutics has lower revenue, but higher earnings than PTC Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than PTC Therapeutics, indicating that it is currently the more affordable of the two stocks.
4.6% of Summit Therapeutics shares are owned by institutional investors. 5.5% of PTC Therapeutics shares are owned by insiders. Comparatively, 88.3% of Summit Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Summary
Summit Therapeutics beats PTC Therapeutics on 10 of the 19 factors compared between the two stocks.
Get PTC Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for PTCT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
PTC Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:PTCT) was last updated on 3/25/2025 by MarketBeat.com Staff
Buy PTCT Stock Free PTCT Stock Alerts